Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.
Authors
Wen Wee Ma
Division of Medical Oncology, Mayo Clinic, Rochester, MN
Wen Wee Ma , Tyler J. Zemla , Daniel Walden , Robert R. McWilliams , Walid Labib Shaib , Daniel H. Ahn , Bassel F. El-Rayes , Thorvardur Ragnar Halfdanarson , Timothy J. Hobday , Sarah Bruggeman , Brandy L. Jaszewski , Fang-Shu Ou , Christina Wu , Tanios S. Bekaii-Saab
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03337087
DOI
10.1200/JCO.2022.40.4_suppl.563
Abstract #
563
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I dose-escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma: Interim update.
First Author: Chao Yin
Poster
2017 Gastrointestinal Cancers Symposium
Phase I study of definitive chemoradiation with gemcitabine and the WEE1 inhibitor AZD1775 in unresectable pancreatic cancer.
First Author: Kyle Clifford Cuneo